MOESM5 of Enrichment of superoxide dismutase 2 in glioblastoma confers to acquisition of temozolomide resistance that is associated with tumor-initiating cell subsets

  • Chia Hung Chien (Contributor)
  • Jian-Ying Chuang (Contributor)
  • Shung-Tai Yang (Contributor)
  • Wen-Bin Yang (Contributor)
  • Pin Yuan Chen (Contributor)
  • Tsung-I Hsu (Contributor)
  • Chih Yuan Huang (Contributor)
  • Wei-Lun Lo (Contributor)
  • Ka-Yen Yang (Contributor)
  • Ming Sheng Liu (Contributor)
  • Jui Mei Chu (Contributor)
  • Pei Hsuan Chung (Contributor)
  • Jr Jiun Liu (Contributor)
  • Shao Wen Chou (Contributor)
  • Shang Hung Chen (Contributor)
  • Kwang Yu Chang (Contributor)



Additional file 5: Figure S5. The assays of tumor-initiating cell (TIC) properties. (A) Tumor formation analysis with limiting dilution (50~1000 cells per injection) of U87-parental and TMZ-resistant (r#10) cells in subcutaneous flank area of NOD-SCID mice was performed and recorded. Tumor formation was defined as the measurement to reach 0.1â cm3 or larger. The number of tumor formation in total implanted mice was shown in the brackets. (B) The frequency of the TIC-featured population of GBM#2 (derived from another recurrent GBM patient) with or without TMZ treatment was estimated using the in vitro extreme limiting dilution assay.
Date made availableJan 1 2019
PublisherUnknown Publisher

Cite this